High-dose therapy followed by autologous stem cell transplantation (ASCT) prolongs survival in patients with multiple myeloma and is relatively safe with treatment-related mortality rates of only 1-5%. Interstitial pneumonitis (IP) is normally an infrequent complication of ASCT with a reported incidence of 0-16%. Between 1992 and 1998, 94 myeloma patients at our center underwent ASCT using a high-dose regimen of etoposide (60 mg/kg), melphalan (160 mg/m 2 ) and fractionated TBI 12 Gy. An unusually high incidence of IP (29/94 (31%)) was noted. Mortality in the IP patients was high at 45%. Patients developing IP were more frequently anemic than those who did not have pulmonary complications (hemoglobin Ͻ100 g/l) prior to transplant (P = 0.03) but no other pre-transplant factors were predictive (ie age, gender, smoking history, CMV status, pulmonary function, creatinine, ␤2-microglobulin or Creactive protein, prior cumulative chemotherapy or chest irradiation). A significantly lower IP rate was noted in 32 contemporaneous myeloma control patients conditioned with BU-CY without TBI at our center (3/32 (9%); P = 0.03) and in 32 lymphoma control patients conditioned with the same melphalan and etoposide regimen minus the TBI (2/32 (6%); P = 0.003). In contrast, when using the same TBI-containing regimen in 32 concurrently treated lymphoma patients, an increase in IP similar to that seen in our myeloma cohort (7/32 (22%); P = 0.3) was noted. This strongly suggests that TBI is the predominant factor contributing to lung toxicity. We conclude that radiation-associated pneumonitis cannot be easily predicted by pretransplant variables. Therefore surveillance, early recognition and prompt therapy are recommended. High-dose therapy followed by autologous stem cell transplantation (ASCT) is now accepted treatment in patients under age 65 with advanced stage multiple myeloma. It is generally considered safe with low treatment-related mortality (TRM) rates of 1-5%. [1] [2] [3] [4] [5] In contrast to the allogeneic setting where pulmonary complications can account for the majority of procedure-related deaths, pneumonitis in the autologous setting is less frequently reported. [6] [7] [8] In patients with multiple myeloma undergoing ASCT, the incidence of pneumonitis is 0-16%. 4, 5, [9] [10] [11] [12] [13] [14] [15] [16] Nevertheless, variation in study populations, treatment regimens and interstitial pneumonitis (IP) diagnostic criteria hamper comparison of patient cohorts between studies.
High-dose therapy followed by autologous stem cell transplantation (ASCT) is now accepted treatment in patients under age 65 with advanced stage multiple myeloma. It is generally considered safe with low treatment-related mortality (TRM) rates of 1-5%. [1] [2] [3] [4] [5] In contrast to the allogeneic setting where pulmonary complications can account for the majority of procedure-related deaths, pneumonitis in the autologous setting is less frequently reported. [6] [7] [8] In patients with multiple myeloma undergoing ASCT, the incidence of pneumonitis is 0-16%. 4, 5, [9] [10] [11] [12] [13] [14] [15] [16] Nevertheless, variation in study populations, treatment regimens and interstitial pneumonitis (IP) diagnostic criteria hamper comparison of patient cohorts between studies.
Typically, IP presents with a clinical picture of cough and dyspnea, hypoxemia, and diffuse non-lobar infiltrates seen on radiologic imaging. Concurrent lung infections may complicate the diagnosis. Variables previously reported to predispose to development of IP include (1) patient-related factors such as premorbid lung disease with pulmonary function testing (PFT) abnormalities, smoking history, concurrent infections, or (2) treatment-related factors such as the use of specific chemotherapeutic agents or irradiation in the preparative regimen and prior localized chest irradiation. 17, 18 In particular, the use of total body irradiation (TBI) in the conditioning regimen has been implicated as a major cause of lung toxicity in both allogeneic and autologous settings. [19] [20] [21] [22] [23] Variation in total radiation dose, the use of lung shielding, dose rates, and fractionation of TBI may influence the incidence and severity of lung toxicity in any one population. 21 From 1992 to 1998, 94 patients with multiple myeloma underwent ASCT using an escalated TBI-containing conditioning regimen at the Toronto Hospital. 24 Patients received an intensified transplant regimen with the addition of etoposide (60 mg/kg), increased dose of melphalan (160 mg/m 2 ) and greater radiation dose (total 12 Gy) than that used in the IFM 90 trial. 1 A surprisingly high incidence of IP was noted in these patients with 29 of 94 patients (31%) developing a clinical picture of IP with a high associated mortality. We have investigated this cohort of patients to better define disease features and outcomes, and to determine if any pre-transplant variables were predictive for development of pneumonitis.
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Patients and methods
Patients
From March 1992 to May 1998, 94 patients with multiple myeloma underwent ASCT at the Toronto Hospital using a TBI-based conditioning regimen. Patient charts were retrospectively reviewed for presence of clinically evident pneumonitis and for risk factors predisposing to pulmonary complications developing post transplantation. Full PFT testing was performed on all patients routinely prior to transplant but those with abnormalities were not excluded from the procedure.
Three additional transplant populations from the same 6 year time-frame as our study cohort were included in the review as control groups: (1) 32 patients with non-Hodgkin's lymphoma transplanted using an identical cytoreductive regimen of melphalan, etoposide, and TBI 12 Gy in order to evaluate the influence of underlying cancer type upon IP incidence. (2) 35 patients with non-Hodgkin's lymphoma transplanted using melphalan and etoposide alone as a non-TBI comparison group. (3) 32 patients with myeloma transplanted using an alternative non-TBI conditioning regimen (busulfan and cyclophosphamide) in order to provide a same-disease comparison group to segregate diseasespecific predisposition to pneumonitis.
Transplantation regimens
Ninety-four patients received a standard conditioning regimen of etoposide 60 mg/kg given on day −4, melphalan 160 mg/m 2 on day −3, and TBI 12 Gy given in six fractions of 2 Gy twice a day on days −2, −1 and 0. Interfraction interval was a minimum of 6 h. Lung shielding produced an effective lung dose of 12 Gy with dose rates of 0.25-0.56 Gy/min. The cobalt source used for irradiation was changed in late 1995 which resulted in a higher dose rate immediately after the change and accounted for the variation in the range. Unmanipulated peripheral blood stem cells were reinfused on day 0. All patients had previously undergone peripheral blood stem cell mobilization with G-CSF 5-10 g/kg and high-dose cyclophosphamide (2.5-4 g/m 2 ). In addition, 32 myeloma patients reviewed as non-TBI controls received the conditioning regimen of busulfan 14 mg/kg and cyclophosphamide 120 mg/kg (BU-CY). These patients were registered under a randomized study using the CEPRATE system (CellPro, Brothell, WA, USA) for peripheral blood stem cell collection. 25 Cyclophosphamide 2.5 g/m 2 , prednisone 2 mg/kg/day orally × 4 days, G-CSF 10 g/kg were used for stem cell mobilization. These patients were treated within 6 months of diagnosis.
All patients were nursed in single reverse isolation rooms and received low microbial diets. Patients received prophylactic ciprofloxacin, acyclovir, nystatin and ranitidine. Irradiated blood products (negative for cytomegalovirus (CMV) if recipients were CMV-seronegative) were used for transfusion support. Parenteral broad-spectrum antibiotics were used for suspected infections during the neutropenic period. Daily blood work including complete blood count, renal function, liver enzymes and electrolytes was performed routinely.
Interim analysis
A high incidence of pneumonitis was noted during interim analysis of this protocol. However, it was noted that patients treated to that point had received considerable prior therapy. Newly diagnosed patients were being enrolled on a multi-center randomized trial (CellPro) and only patients with more than 6 months prior treatment were placed on the TBI-conditioning regimen. It was therefore anticipated that the complication rate would drop as the CellPro trial ended and less heavily pre-treated patients received TBI. The regimen therefore continued to be used until an ongoing high incidence of IP resulted in discontinuation.
Data collection
Data was retrieved by chart review and included the following: subtype and stage of myeloma, history of smoking, pre-transplant CMV serological status, laboratory values at diagnosis and transplant (hemoglobin (Hb), creatinine, lactate dehydrogenase (LDH), percentage of bone marrow plasmacytosis, C-reactive protein (CRP) or ␤2-microglobulin), type and duration of chemotherapy regimens and radiotherapy employed prior to admission for ASCT, conditioning regimen employed, development of IP including investigations performed to confirm diagnosis, IP treatment and survival outcome. Pre-transplant PFT values were documented including forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), diffusing capacity (DLCO) corrected for reduced hemoglobin 26 and total lung capacity (TLC). All available medical records, autopsy reports, and surgical pathology reports were reviewed.
Diagnostic criteria
Interstitial pneumonitis was defined as a clinical syndrome developing post transplant with respiratory symptoms (commonly dyspnea and non-productive cough), Ϯ hypoxemia and radiologic evidence of non-lobar pulmonary infiltrates without evidence of congestive heart failure. The presence of fungal, viral or bacterial agents isolated from pulmonary tissue or secretions was noted but did not preclude the diagnosis of IP if clinical evaluation did not initially support an infectious etiology.
Statistical analysis
Statistical analyses were performed with the SPPS software package (SPPS, Chicago, IL, USA). Covariates in the patient cohorts with or without pneumonitis were compared with Fisher's exact test or the chi-square test. 27 Survival curves were determined according to the Kaplan-Meier method 28 with comparison between groups calculated using the log-rank test. 29 
Results
IP disease characteristics
Median interval from transplant to development of pulmonary symptoms was 9.4 weeks (range 5 days to 8 months). All patients developed IP within 4 months of transplantation except one patient who was diagnosed with late interstitial fibrosis at 8 months. Dyspnea and/or cough were the main presenting symptoms. Thirteen of the 29 patients had documented fever at presentation. Fever and hypoxemia were the usual indications for hospitalization. Seventeen patients were hospitalized, with 10 requiring intubation and ventilation. Infectious agents were concurrently isolated in seven (24%) patients at some point during hospitalization. Eleven of the 17 hospitalized patients received antibiotic therapy with 10 patients receiving high-dose steroids for empiric treatment of radiation pneumonitis (four patients received both). Only four of the hospitalized patients had been started on steroid therapy within 7 days of symptomsall others had delayed onset due to lack of initial suspicion for radiation-associated IP. Of the 10 patients requiring ventilator support, only one patient survived to leave the hospital. Of the 12 patients managed as outpatients, three received antibiotic therapy and 10 received steroid therapy (one patient received both). All outpatients improved and have either discontinued therapy or are in the process of tapering off steroids.
In total, acute mortality after developing IP was 45% 
Patient characteristics do not predict for pneumonitis
Pre-transplant patient characteristics in both pneumonitis and non-pneumonitis groups are outlined in Table 1 . Overall median age was 53 years (range 32-69 years). There was no significant difference in median age, gender, or CMV status at transplant between both groups. In each cohort where reliable smoking data were available, 40% of patients had a smoking history (10/25 IP patients, 20/50 non-IP patients). Disease characteristics are outlined in Table 2 . A greater proportion of patients who developed pulmonary complications had hemoglobin levels less than 100 gl at transplant (9/29 (31%) vs 8/64 (12%) in the non-IP group; P = 0.03). No other significant differences between the groups were noted.
Prior therapy does not predict for pneumonitis
As outlined in Table 3 , time from diagnosis to transplant was similar in both groups. In general, the entire cohort of patients was heavily pretreated with 74% of all patients transplanted over 1 year from diagnosis. Median follow-up from transplant was 11.8 months (range 3.4 months to 6 years). Pre-transplant treatment did not influence rates of Table 2 Pre-transplant disease characteristics and after the cobalt source change, a potential cause of altered dose rates, was noted (P = 0.32). Table 4 shows PFT values performed as part of the routine pre-transplant assessment. DLCO abnormalities were common in the total cohort (33%) but were not more frequent in patients who went on to develop pneumonitis post transplant (DLCO р75% of predicted in the IP group 9/29 (31%), non-IP group 22/65 (34%); P = 0.93). No significant differences in numbers of patients with abnormal values for FEV1, FVC, and TLC were noted between the two groups. Standard cutoff levels for abnormal PFT values as determined by the respirology department at our center were used.
Pneumonitis
Non-P value (%) (n = 29) pneumonitis (%) (n = 65)
Pulmonary function tests do not predict for development of pneumonitis
Pneumonitis outcomes in control groups
Of the 35 control patients with lymphoma who received etoposide and melphalan without TBI, only two (6%) 26 developed pneumonitis post transplant. This IP incidence is significantly lower than the 31% incidence noted in our myeloma study group (P = 0.003). A low incidence of pneumonitis was also noted in the 32 myeloma patients who received BU-CY conditioning without TBI (9.4%) (P = 0.03). In contrast, of the 32 control patients with lymphoma who received the identical regimen of etoposide, melphalan and TBI 12 Gy, seven (22%) developed pulmonary complications which is statistically comparable to the IP incidence of 31% in our myeloma study group (P = 0.33).
Discussion
Therapy-related toxicity is often implicated as a cause of pneumonitis after bone marrow transplantation. In many cases, TBI in the conditioning regimen is speculated as initiating pulmonary damage. We report in the present study a 31% rate of IP in patients receiving TBI in the preparatory regimen as compared to a significantly lower rate in lymphoma patients conditioned with the same regimen without TBI (P = 0.003) or in myeloma patients treated with a different non-TBI containing regimen of BU-CY (P = 0.03). When using the identical TBI-containing regimen, however, in a cohort of lymphoma patients, we again note an increase in IP comparable to that of our myeloma study group (P = 0.33). Although factors intrinsic to the underlying disease itself or to prior disease-specific treatment may contribute to lung toxicity, these data suggest that TBI supersedes as the predominant predisposing factor. Doses of TBI used in transplantation range from 2.85 to 16 Gy with varying degrees of lung shielding, given in 1-10 fractions, at dose rates from 0.02 to more than 0.3 Gy/min. 8 In our study, we used fractionated TBI with an effective lung dose of 12 Gy following shielding. Our dose rates of 0.25-0.56 Gy/min varied chiefly due to the change in cobalt source during our study period but this did not appear to influence IP incidence. The intensified radiation schema used at our center represents one of the highest total radiation doses and dose rates used in myeloma conditioning regimens in the literature but is not exceptional in other hematologic neoplasms.
1,5,9,13 Varterasian et al 13 performed autologous or allogeneic transplants on 48 myeloma patients with most receiving high-dose chemotherapy plus TBI 12 Gy in four to six fractions with variable lung shielding in the conditioning regimen, similar to our TBI regimen. Dose rates were not reported. As opposed to our patient cohort, only one patient (allogeneic) developed pulmonary complications (viral pneumonia). In a study of 100 patients with non-Hodgkin's lymphoma undergoing ABMT using a 12 Gy TBI schedule with shielding to decrease the lung dose by 10% (dose rate of 0.1 Gy/min), Jochelson et al 30 reported an IP incidence of only 7.6% with a low IP-related mortality of 1%. All patients received high-dose cyclophosphamide plus TBI for the preparatory regimen. Also, registry data including patients receiving TBI of 12 Gy total dose (dose rates not published) report low incidence rates of pulmonary complications. 5 Prior chest irradiation may enhance the toxic effect of TBI on the lung. 17 We, however, did not find a significant difference in prior chest irradiation between our IP and non-IP patients. Cumulative chemotherapy toxicity in conjunction with TBI may contribute to lung damage. Weiner et al 31 reported a correlation between higher dose rates of TBI and pneumonitis in allogeneic transplant recipients only when combined with methotrexate therapy. This synergistic toxic effect of irradiation and drug therapy has also been noted by others. [32] [33] [34] Many of our 94 patients receiving TBI had prior exposure to agents known to cause lung toxicity. Sixty-seven (71%) patients received adriamycin 35 as part of the VAD regimen, 5/94 (5%) BCNU, and 18/94 (19%) cyclophosphamide as myeloma therapy (all patients received cyclophosphamide for stem cell mobilization). Use of these agents or number of prior chemotherapy regimens did not, however, independently influence lung complication rates in our patients. It is uncertain if melphalan, either in conventional doses or in high-dose therapy as part of conditioning pre-transplant, predisposes to IP. Rare case reports have linked melphalan to pulmonary fibrosis 36, 37 but more recent clinical studies have not supported this link. 13, 38, 39 Although busulfan is well known to cause pulmonary damage, we noted a significantly lower rate of IP in the control patients who received BU-CY as pre-transplant conditioning. Etoposide, used in our preparatory regimen, has not been linked with lung toxicity.
In this report, we aimed to identify pre-transplant variables which may predict for development and outcome of post-transplant lung disease. Only pre-transplant hemoglobin less than 100 g/l was identified as a significant factor. Pre-transplant hemoglobin may reflect greater tumor burden or disease activity although other substitute markers such as pre-transplant bone marrow plasmacytosis, LDH, CRP and ␤2-microglobulin were not found to be significantly different between the IP and non-IP groups. A low hemoglobin at the time of transplant may also reflect less reserve to tolerate the toxic effects of treatment. Older age (greater than age 50), smoking history and renal insufficiency have previously been reported to be predictive of IP development but were not found to be significant risks in our study. 17, 18, 22, 31 Many investigators have attempted to predict post-transplant lung damage by pre-transplant PFT abnormalities. A restrictive ventilatory defect and decreased diffusing capacity pre-transplant have been associated with early post-transplant pulmonary complications and an increased risk of death. Others have reported no correlation between PFT testing and pulmonary complications. 40 Approximately a third of our myeloma patients had a significantly low DLCO prior to transplant. When compared between the IP and non-IP groups, we could find no predictive value of pre-transplant DLCO or of any other single pulmonary function test abnormality. Inability to rely on pre-transplant factors to predict for development of IP emphasizes the need for early recognition, prompt treatment and supportive care. Unfortunately, despite aggressive treatment, we report a high mortality rate (45%) and median survival of only 4.6 months (Ϯ 19.2 months) after IP diagnosis. In general, patients who were promptly treated with steroids (within 7 days of symptoms) and did not require hospitalization had improved outcomes. Unfortunately, delays in steroid therBone Marrow Transplantation apy often occurred, particularly in patients hospitalized at non-transplant centers with fever where infectious pneumonia was presumed and radiation-associated pneumonitis was not initially suspected. From our experience, we emphasize the recognition of pulmonary toxicity from radiation and encourage prompt steroid therapy at first sign of respiratory symptoms.
Over the past years, refinement in transplant technique has rendered autologous transplantation a safe upfront approach in multiple myeloma. Unfortunately, this approach does not lead to cure, with disease eventually recurring in all patients. Attempts to improve outcomes with intensified treatment may lead to unexpected toxicity as evident from our experience. Our data suggest that fractionated TBI (12 Gy) using a high dose rate, when used with intensified melphalan and etoposide, may be a major contributing factor to development of pneumonitis leading to an unacceptably high rate of treatment-related mortality.
